178 related articles for article (PubMed ID: 30289729)
21. Effects of the lysosomal destabilizing drug siramesine on glioblastoma in vitro and in vivo.
Jensen SS; Petterson SA; Halle B; Aaberg-Jessen C; Kristensen BW
BMC Cancer; 2017 Mar; 17(1):178. PubMed ID: 28270132
[TBL] [Abstract][Full Text] [Related]
22. Identification of novel small-molecule inhibitors of glioblastoma cell growth and invasion by high-throughput screening.
Wang L; Zhao H; Cui K; Yao L; Ren M; Hao A; Smollen P; Nie F; Jin G; Liu Q; Wong ST
Biosci Trends; 2012 Aug; 6(4):192-200. PubMed ID: 23006966
[TBL] [Abstract][Full Text] [Related]
23. Scaffold-based spheroid models of glioblastoma multiforme and its use in drug screening.
Manikandan C; Jaiswal AK
Biotechnol Bioeng; 2023 Aug; 120(8):2117-2132. PubMed ID: 37366303
[TBL] [Abstract][Full Text] [Related]
24. Longitudinal stability of molecular alterations and drug response profiles in tumor spheroid cell lines enables reproducible analyses.
Nickel AC; Picard D; Qin N; Wolter M; Kaulich K; Hewera M; Pauck D; Marquardt V; Torga G; Muhammad S; Zhang W; Schnell O; Steiger HJ; Hänggi D; Fritsche E; Her NG; Nam DH; Carro MS; Remke M; Reifenberger G; Kahlert UD
Biomed Pharmacother; 2021 Dec; 144():112278. PubMed ID: 34628166
[TBL] [Abstract][Full Text] [Related]
25. PTEN deficiency leads to proteasome addiction: a novel vulnerability in glioblastoma.
Benitez JA; Finlay D; Castanza A; Parisian AD; Ma J; Longobardi C; Campos A; Vadla R; Izurieta A; Scerra G; Koga T; Long T; Chavez L; Mesirov JP; Vuori K; Furnari F
Neuro Oncol; 2021 Jul; 23(7):1072-1086. PubMed ID: 33428749
[TBL] [Abstract][Full Text] [Related]
26. Culture dimensionality influences the resistance of glioblastoma stem-like cells to multikinase inhibitors.
Fernandez-Fuente G; Mollinedo P; Grande L; Vazquez-Barquero A; Fernandez-Luna JL
Mol Cancer Ther; 2014 Jun; 13(6):1664-72. PubMed ID: 24723451
[TBL] [Abstract][Full Text] [Related]
27. Development of an in vitro tumor spheroid culture model amenable to high-throughput testing of potential anticancer nanotherapeutics.
Solomon MA; Lemera J; D'Souza GG
J Liposome Res; 2016 Sep; 26(3):246-60. PubMed ID: 26780923
[TBL] [Abstract][Full Text] [Related]
28. Combinatorial Drug Testing in 3D Microtumors Derived from GBM Patient-Derived Xenografts Reveals Cytotoxic Synergy in Pharmacokinomics-informed Pathway Interactions.
Gilbert AN; Anderson JC; Duarte CW; Shevin RS; Langford CP; Singh R; Gillespie GY; Willey CD
Sci Rep; 2018 May; 8(1):8412. PubMed ID: 29849102
[TBL] [Abstract][Full Text] [Related]
29. Real-time viability and apoptosis kinetic detection method of 3D multicellular tumor spheroids using the Celigo Image Cytometer.
Kessel S; Cribbes S; Bonasu S; Rice W; Qiu J; Chan LL
Cytometry A; 2017 Sep; 91(9):883-892. PubMed ID: 28618188
[TBL] [Abstract][Full Text] [Related]
30. Multiparametric Analysis of Oncology Drug Screening with Aqueous Two-Phase Tumor Spheroids.
Shahi Thakuri P; Ham SL; Luker GD; Tavana H
Mol Pharm; 2016 Nov; 13(11):3724-3735. PubMed ID: 27653969
[TBL] [Abstract][Full Text] [Related]
31. Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors.
Rosenberg S; Verreault M; Schmitt C; Guegan J; Guehennec J; Levasseur C; Marie Y; Bielle F; Mokhtari K; Hoang-Xuan K; Ligon K; Sanson M; Delattre JY; Idbaih A
Neuro Oncol; 2017 Feb; 19(2):219-228. PubMed ID: 27571888
[TBL] [Abstract][Full Text] [Related]
32. Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma.
Bikhezar F; de Kruijff RM; van der Meer AJGM; Torrelo Villa G; van der Pol SMA; Becerril Aragon G; Gasol Garcia A; Narayan RS; de Vries HE; Slotman BJ; Denkova AG; Sminia P
J Neurooncol; 2020 Jan; 146(2):239-246. PubMed ID: 31875307
[TBL] [Abstract][Full Text] [Related]
33. Impact of the spheroid model complexity on drug response.
Hoffmann OI; Ilmberger C; Magosch S; Joka M; Jauch KW; Mayer B
J Biotechnol; 2015 Jul; 205():14-23. PubMed ID: 25746901
[TBL] [Abstract][Full Text] [Related]
34. Engineering a Brain Cancer Chip for High-throughput Drug Screening.
Fan Y; Nguyen DT; Akay Y; Xu F; Akay M
Sci Rep; 2016 May; 6():25062. PubMed ID: 27151082
[TBL] [Abstract][Full Text] [Related]
35. Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma.
Narayan RS; Gasol A; Slangen PLG; Cornelissen FMG; Lagerweij T; Veldman HYYE; Dik R; van den Berg J; Slotman BJ; Würdinger T; Haas-Kogan DA; Stalpers LJA; Baumert BG; Westerman BA; Theys J; Sminia P
Mol Cancer Ther; 2018 Feb; 17(2):347-354. PubMed ID: 28958992
[TBL] [Abstract][Full Text] [Related]
36. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
[TBL] [Abstract][Full Text] [Related]
37. High Content Screening Characterization of Head and Neck Squamous Cell Carcinoma Multicellular Tumor Spheroid Cultures Generated in 384-Well Ultra-Low Attachment Plates to Screen for Better Cancer Drug Leads.
Kochanek SJ; Close DA; Johnston PA
Assay Drug Dev Technol; 2019 Jan; 17(1):17-36. PubMed ID: 30592624
[TBL] [Abstract][Full Text] [Related]
38. A polymer microstructure array for the formation, culturing, and high throughput drug screening of breast cancer spheroids.
Markovitz-Bishitz Y; Tauber Y; Afrimzon E; Zurgil N; Sobolev M; Shafran Y; Deutsch A; Howitz S; Deutsch M
Biomaterials; 2010 Nov; 31(32):8436-44. PubMed ID: 20692698
[TBL] [Abstract][Full Text] [Related]
39. Combined treatment with 2'-hydroxycinnamaldehyde and temozolomide suppresses glioblastoma tumorspheres by decreasing stemness and invasiveness.
Jeong H; Park J; Shim JK; Lee JE; Kim NH; Kim HS; Chang JH; Yook JI; Kang SG
J Neurooncol; 2019 May; 143(1):69-77. PubMed ID: 30887242
[TBL] [Abstract][Full Text] [Related]
40. Engineered 3D tumour model for study of glioblastoma aggressiveness and drug evaluation on a detachably assembled microfluidic device.
Ma J; Li N; Wang Y; Wang L; Wei W; Shen L; Sun Y; Jiao Y; Chen W; Liu J
Biomed Microdevices; 2018 Sep; 20(3):80. PubMed ID: 30191323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
